IMPORTANCE Current models of Goltz syndrome cannot estimate the overall neocollagenesis and marked shift in collagen types after ablative fractional laser resurfacing (AFR) within treated areas of focal dermal hypoplasia (FDH).
G oltz syndrome is an X-linked dominant disorder most commonly affecting the skin, eyes, teeth, and skeleton. 1 The condition is caused by heterozygous and mosaic PORCN (HGNC 17652) gene mutations located on Xp11.23. 2, 3 This region encodes an endoplasmic reticulum membrane protein involved in regulation of the Wnt signaling pathway, which plays a crucial role in mesoderm and ectoderm development. 4 Nearly 120 different mutations have been identified; however, owing to the overall complexity of the Wnt pathway and the specific underlying pathophysiologic features of Goltz syndrome, neither severity nor presentation can be estimated based on a specific mutation at this time.
5-7 Dermatologic signs are often present at birth and include aplasia cutis congenita, telangiectasias, nodular fat herniations (ie, outpouchings), pigmentary alterations, dystrophic nails, thin and brittle hair, papillomas, and focal dermal hypoplasia (FDH) in a blaschkoid distribution. 1, 8 Histologic evaluation of mosaically affected FDH demonstrates an atrophic dermis, increased dermal adipocytes, increased papillary dermal capillaries, abnormal fibroblasts, and sparse, disorganized collagen. [9] [10] [11] The mechanism by which the excess fat enters the dermis remains controversial; theories include decreased collagen allowing for displacement of subdermal adipocytes into the dermis vs adipocyte overgrowth within the dermis. To our knowledge, no reports of spontaneous resolution within mosaically affected skin have been published. Likewise, the specific ratio of collagen types within the abnormal network present in patients with Goltz syndrome has yet to be characterized, and no attempts to improve FDH directly through inducement of neocollagenesis have been published.
Ablative fractional laser resurfacing (AFR) has been shown to induce collagen remodeling in burn scars, chronic wounds, and epidermolysis bullosa. [12] [13] [14] [15] We hypothesized that the local effects of AFR might induce neocollagenesis and help fortify the type III collagen present at baseline in the mosaically affected areas of FDH despite the patient's genetic predisposition to the contrary.
Methods
A female infant presented with erosion and fat herniation of the left posterior leg, microphthalmia, ocular coloboma and blindness of the left eye, lop ear deformity, left third and fourth finger syndactyly, and left great toe polydactyly. She was subsequently diagnosed with Goltz syndrome by the late Robert Goltz, MD. More than a decade later, she sought treatment for self-described red, itchy skin within a large plaque of FDH on her left posterior thigh and calf ( Figure 1A ). This area was cosmetically distressful and physically debilitating because the loose skin was easily traumatized, irritated, and extremely pruritic. The possibility of AFR was introduced, and the family elected to proceed with treatment. Informed parental consent and patient assent were obtained. The patient underwent 2 sessions of fractional photothermolysis approximately 2 months apart using general anesthesia for pain management. Both treatments were performed with an ablative microfractionated carbon dioxide laser (Ultrapulse Deep FX; Lumenis, Ltd) at 35 mJ and 10% density for the first treatment and at 20 mJ and 10% density for the second treatment ( Figure 1B) ; microspot size was fixed at approximately 0.12 mm. A petrolatum-based ointment was applied to the wound 3 times daily for 2 weeks. Biopsy specimens of mosaically affected skin and adjacent, unaffected skin (ie, internal control specimens) were obtained before the initial AFR treatment and 8 weeks after the final treatment.
Results
Subjectively, the patient reported decreased pruritus and a reduction in local trauma after AFR. Clinically, tightening and thickening of her treated area were noticeable, with less outpouching and skin laxity ( Figure 1C-E) . On histologic analysis, both internal controls had findings consistent with normal skin (Figure 2A and B). Before treatment, mosaically affected skin revealed striking attenuation of dermal collagen and loss of elastic tissue, consistent with FDH ( Figure 2C ). After treatment, mosaically affected skin revealed thickening and fibrosis of the dermal collagen, increased vascularity, and no change in elastin ( Figure 2D ). Herovici collagen staining of normal skin demonstrated a predominance of type I collagen ( Figure 3A) . In contrast, mosaically affected skin revealed a baseline predominance of type III collagen before treatment ( Figure 3B ). After treatment, however, mosaically affected skin showed a marked shift toward type I collagen ( Figure 3C ). The patient's subjective improvement and observed clinical changes have persisted more than 6 months postoperatively. We plan to follow up with the patient in 1 year to assess whether retreatment of the affected area is necessary.
Discussion
Ablative fractional laser resurfacing has been shown to induce neocollagenesis, leading to an increased ratio of type III
Key Points
Question How might ablative fractional laser resurfacing alter local collagen composition within areas of focal dermal hypoplasia associated with Goltz syndrome?
Findings In this case report of a patient with Goltz syndrome, histologic changes demonstrated that, compared with internal controls, mosaically affected areas of focal dermal hypoplasia treated with ablative fractional laser resurfacing appear objectively to thicken. A marked shift in collagen predominance from type III (fetal/early wound) to type I (adult/mature) was found.
Meaning Thermal microtrauma caused by ablative fractional laser resurfacing may create a unique environment that activates latent genes, inducing neocollagenesis and allowing this patient with Goltz syndrome to adaptively produce the collagen subtype that was specifically deficient at baseline. to type I collagen. The mechanism underlying this process has yet to be fully elucidated and involves the induction of growth factors, including increasing transforming growth factor β 3 expression, decreasing basic fibroblast growth factor expression, and increasing matrix metalloproteinase-1 expression and involvement of microRNAs (especially miR-18a and miR-19a).
12,13
Management of FDH in Goltz syndrome poses a clinical challenge because of the inability to correct or overcome the underlying genetic mutation and elicit neocollagenesis. Histologic features of FDH demonstrate an atrophic dermis, numerous subepidermal adipocytes, and a disorganized, diminished collagen network.
9,11 A potential explanation for the defective collagen network based on studies of electron micrographs is that the affected fibroblasts are dysfunctional. 9 No published reports, to our knowledge, have defined the specific ratios of type I to type III collagen expression within areas of FDH in patients with Goltz syndrome. Our Herovici collagen stains revealed a baseline predominance of type III collagen that shifted markedly to a type I predominance after AFR. This finding was unexpected for 2 reasons. First, patients with Goltz syndrome, because of their underlying genetic mutation, do not show spontaneous clinical improvement within areas of FDH after normal macrotrauma. Second, AFR has been previously associated with a shift toward type III collagen predominance in treatment of burn scars.
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These clinical and histologic observations could not have been anticipated using current models of Goltz syndrome. We surmise that the thermal microtrauma caused by AFR creates wounds from which the human body has yet to evolve the means for healing normally. In this case, AFR may have induced neocollagenesis through an alternative or as yet unknown pathway, allowing the patient to adaptively produce the type of collagen that was deficient at baseline, effectively overcoming genetic programming in local areas of FDH. This phenomenon, if true, may be analogous to the use of hydroxyurea to increase the ratio of fetal hemoglobin in patients with sickle cell anemia, with local effects of AFR appearing to stimulate type I collagen production. The patient's unaffected, adjacent skin served as an internal control throughout the treatment duration. Histologic findings also confirm that the tissue specimens were not switched because the overall Goltz architecture was preserved through the mosaically affected stains albeit to a lesser extent in the post-AFR specimens.
Limitations
This report is limited by the study of a single patient. The field would benefit from rigorous long-term prospective trials.
Conclusions
Although further study is needed to confirm the overall efficacy of an AFR protocol for the treatment of FDH plaques in patients with Goltz syndrome, our report shows promising results and raises important questions about gene expression and the epigenetics of Goltz syndrome-associated mutations and the local effects of AFR. A dearth of treatment options exists for the cutaneous manifestations of Goltz syndrome, and the skin defects may be distressing to affected patients. In addition to the clinical benefits afforded by AFR, this novel technique may help reveal 
